Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohn's disease: results of 2 Phase 2b randomised placebo-controlled trials

被引：0
|
作者：
Panes, J. [1 ]
Moscariello, M. [2 ]
Maller, E. [2 ]
Chan, G. [2 ]
Wang, W. [2 ]
Healey, P. [3 ]
机构：
[1] Hosp Clin Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, Groton, CT 06340 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP053
引用
收藏
页码：S60 / S61
页数：2
相关论文
共 50 条
  • [21] Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept
    Tyring, S.
    Bagel, J.
    Lynde, C.
    Klekotka, P.
    Thompson, E. H. Z.
    Gandra, S. R.
    Shi, Y.
    Kricorian, G.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (01) : 125 - 128
  • [22] Tofacitinib pharmacokinetics and durability of drug exposure in moderate-to-severe Crohn's disease patients in Phase 2 induction and maintenance studies
    Mukherjee, A.
    Deng, C.
    Xie, R.
    Martin, S. W.
    Chan, G.
    Moscariello, M.
    Niezychowski, W.
    Maller, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S314 - S314
  • [23] The patient-reported burden of atopic dermatitis and its association with itch: Observations from the upadacitinib phase 2b randomized, placebo-controlled trial in moderate to severe atopic dermatitis
    Silverberg, Jonathan I.
    Calimlim, Brian
    Teixeira, Henrique D.
    Wu, Meijing
    Simpson, Eric L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB77 - AB77
  • [24] Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis
    Poulin, Y.
    Ramon, M.
    Rosoph, L.
    Weisman, J.
    Mendelsohn, A. M.
    Parno, J.
    Rozzo, S. J.
    Lee, P.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (07) : 1500 - 1509
  • [25] Achieving a deep response on patient-reported outcomes with upadacitinib in patients with moderate-to-severe atopic dermatitis: results from three phase III trials
    Chovatiya, R.
    Schuttelaar, M. -L.
    Calimlim, B.
    Liu, Y.
    Takemoto, S.
    Staender, S.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E161 - E161
  • [26] Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
    Valenzuela, F.
    Paul, C.
    Mallbris, L.
    Tan, H.
    Papacharalambous, J.
    Valdez, H.
    Mamolo, C.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (10) : 1753 - 1759
  • [27] LEBRIKIZUMAB IMPROVES PATIENT-REPORTED SYMPTOMS OF ANXIETY AND DEPRESSION IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM THREE RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 3 TRIALS
    Lio, Peter
    Armstrong, April
    Guenthner, Scott
    Gutermuth, Jan
    Zhong, Jinglin
    Pierce, Evangeline
    Dawson, Zach
    Witte, Michael
    Thyssen, Jacob P.
    Wollenberg, Andreas
    [J]. ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 31
  • [28] Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
    Thaci, Diamant
    Simpson, Eric L.
    Beck, Lisa A.
    Bieber, Thomas
    Blauvelt, Andrew
    Papp, Kim
    Soong, Weily
    Worm, Margitta
    Szepietowski, Jacek C.
    Sofen, Howard
    Kawashima, Makoto
    Wu, Richard
    Weinstein, Steven P.
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Teper, Ariel
    Sutherland, E. Rand
    Mastey, Vera
    Stahl, Neil
    Yancopoulos, George D.
    Ardeleanu, Marius
    [J]. LANCET, 2016, 387 (10013): : 40 - 52
  • [29] Upadacitinib improved patient-reported sleep in moderate-to-severe atopic dermatitis: results from a phase zb randomized, placebo controlled trial
    Reich, K.
    Liu, M.
    Calimlim, B.
    Teixeira, H. D.
    Silverberg, J. I.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 60 - 61
  • [30] Dupilumab Improves Patient-Reported Outcomes (PROs) in a Phase 2 Study in Adults with Moderate-to-Severe Atopic Dermatitis
    Simpson, Eric
    Worm, Margitta
    Soong, Weily
    Blauvelt, Andrew
    Eckert, Laurent
    Wu, Richard
    Ardeleanu, Marius
    Graham, Neil
    Pirozzi, Gianluca
    Sutherland, E. Rand
    Mastey, Vera
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB167 - AB167
12345